Pages that link to "Q46952175"
Jump to navigation
Jump to search
The following pages link to Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept (Q46952175):
Displaying 24 items.
- Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis (Q21202966) (← links)
- Biologics in dermatology: an integrated review (Q27004638) (← links)
- Sweet Syndrome due to Myelodysplastic Syndrome: Possible Therapeutic Role of Intravenous Immunoglobulin in Addition to Standard Treatment (Q33762232) (← links)
- Neutrophilic skin lesions in autoimmune connective tissue diseases: nine cases and a literature review (Q36151831) (← links)
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 (Q36171750) (← links)
- Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet's syndrome) (Q37853609) (← links)
- Tumor necrosis factor biologics beyond psoriasis in dermatology (Q37886194) (← links)
- Sweet's syndrome with idiopathic thrombocythemia (Q38262390) (← links)
- Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review (Q39452476) (← links)
- Sweet's syndrome after adalimumab therapy for refractory relapsing polychondritis (Q39995275) (← links)
- Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome (Q40328703) (← links)
- Etanercept treatment of erythema nodosum (Q40445169) (← links)
- Evidence of differentiation in myeloid malignancies associated neutrophilic dermatosis: a fluorescent in situ hybridization study of 14 patients (Q44631061) (← links)
- Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides. (Q48332071) (← links)
- Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients (Q50581879) (← links)
- Histiocytoid Sweet syndrome successfully treated with etanercept. (Q55063888) (← links)
- Insights Into the Pathogenesis of Sweet's Syndrome (Q64102256) (← links)
- [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] (Q80516806) (← links)
- [Etanercept. Other indications] (Q84279889) (← links)
- Management of neutrophilic dermatoses (Q84480188) (← links)
- Thalidomide in the Treatment of Sweet's Syndrome and Eosinophilic Folliculitis Associated With Immune Reconstitution Inflammatory Syndrome (Q89623423) (← links)
- Insights Into the Characteristics of Sweet Syndrome in Patients With and Without Hematologic Malignancy (Q90056995) (← links)
- Recurrent Idiopathic Sweet Syndrome - Case Report and Literature Review (Q97422512) (← links)
- Biologics in Dermatology: Off-Label Indications (Q97645901) (← links)